Axonics (NASDAQ:AXNX) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Axonics (NASDAQ:AXNX) in a research report sent to investors on Monday, Benzinga reports.

Axonics Stock Up 0.1 %

Axonics stock traded up $0.09 during trading hours on Monday, hitting $68.71. The stock had a trading volume of 396,265 shares, compared to its average volume of 844,940. The company has a 50-day moving average of $67.59 and a two-hundred day moving average of $67.72. Axonics has a fifty-two week low of $48.30 and a fifty-two week high of $69.68. The company has a market cap of $3.51 billion, a PE ratio of -214.44 and a beta of 0.83.

Axonics (NASDAQ:AXNX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. The business had revenue of $114.57 million for the quarter, compared to analysts’ expectations of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. Axonics’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. As a group, analysts forecast that Axonics will post 0.13 EPS for the current fiscal year.

Institutional Trading of Axonics

Several institutional investors have recently made changes to their positions in AXNX. Headlands Technologies LLC lifted its holdings in shares of Axonics by 31.1% during the first quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock valued at $77,000 after acquiring an additional 265 shares during the period. NBC Securities Inc. lifted its holdings in Axonics by 106.4% during the 4th quarter. NBC Securities Inc. now owns 673 shares of the company’s stock valued at $41,000 after purchasing an additional 347 shares during the last quarter. Arizona State Retirement System boosted its position in Axonics by 2.5% in the second quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock valued at $960,000 after buying an additional 355 shares in the last quarter. Scholtz & Company LLC grew its stake in Axonics by 7.8% during the fourth quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock worth $310,000 after buying an additional 360 shares during the last quarter. Finally, Whittier Trust Co. increased its holdings in shares of Axonics by 59.1% during the first quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after buying an additional 424 shares in the last quarter. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.